1. Home
  2. NPKI vs XERS Comparison

NPKI vs XERS Comparison

Compare NPKI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NPK International Inc.

NPKI

NPK International Inc.

HOLD

Current Price

$15.76

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.24

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPKI
XERS
Founded
1932
2005
Country
United States
United States
Employees
510
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NPKI
XERS
Price
$15.76
$6.24
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$14.17
$10.83
AVG Volume (30 Days)
754.4K
1.2M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
N/A
Revenue
N/A
$49,590,000.00
Revenue This Year
$16.39
$34.37
Revenue Next Year
$11.70
$22.86
P/E Ratio
$38.65
N/A
Revenue Growth
N/A
142.67
52 Week Low
$7.63
$4.30
52 Week High
$16.50
$10.08

Technical Indicators

Market Signals
Indicator
NPKI
XERS
Relative Strength Index (RSI) 57.11 55.09
Support Level $13.58 $5.79
Resistance Level N/A $6.41
Average True Range (ATR) 0.81 0.21
MACD 0.04 0.02
Stochastic Oscillator 69.80 62.99

Price Performance

Historical Comparison
NPKI
XERS

About NPKI NPK International Inc.

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: